胆汁淤积性肝病婴儿粪便中细菌相关代谢产物短链脂肪酸水平的分析

李檬; 刘四香; 王明英; 刘梅; 胡红卫; 丁臻博; 黄永坤

doi:10.7499/j.issn.1008-8830.2019.07.011

PDF(1225 KB)

HTML

中国当代儿科杂志 ›› 2019, Vol. 21 ›› Issue (7) : 676-679. DOI: 10.7499/j.issn.1008-8830.2019.07.011

论著·临床研究

胆汁淤积性肝病婴儿粪便中细菌相关代谢产物短链脂肪酸水平的分析

李檬^1,2, 刘四香³, 王明英³, 刘梅¹, 胡红卫^1,2, 丁臻博¹, 黄永坤^1,2

作者信息 +

Levels of short-chain fatty acids in enterobacteria-related metabolites in the feces of infants with cholestatic hepatopathy

LI Meng^1,2, LIU Si-Xiang³, WANG Ming-Ying³, LIU Mei¹, HU Hong-Wei^1,2, DING Zhen-Bo¹, HUANG Yong-Kun^1,2

Author information +

文章历史 +

摘要

目的比较婴儿胆汁淤积性肝病（ICH）患儿和健康婴儿粪便中细菌相关代谢产物短链脂肪酸的差异，并探讨其临床意义。方法选取诊断为ICH患儿30例，另选取健康婴儿30例为对照组。收集ICH患儿治疗前组、治疗后组和对照组的粪便标本。应用气相色谱技术定量测定各组婴儿粪便中短链脂肪酸包括乙酸、丙酸、丁酸、异丁酸、异戊酸的含量，并进行比较。结果对照组、治疗前组、治疗后组的乙酸、丙酸浓度差异无统计学意义（P > 0.05），治疗后组丁酸浓度较治疗前组升高（P < 0.05）。对照组异丁酸、异戊酸浓度高于治疗前组及治疗后组（P < 0.05）。结论 ICH患儿的肠道蛋白质代谢产物与正常婴儿存在差异，而碳水化合物代谢产物差异不显著。

Abstract

Objective To compare the levels of short-chain fatty acids in enterobacteria-related metabolites in feces between infants with cholestatic hepatopathy and healthy infants. Methods Thirty infants with cholestatic hepatopathy were enrolled in this study as the disease group, while 30 healthy infants were enrolled as the control group. Fecal specimens were collected from the disease group before and after treatment and from the control group. Gas chromatography was used to quantitatively determine the content of short-chain fatty acids in the feces of both groups including acetic acid, propionic acid, butyric acid, isobutyric acid, and isovaleric acid. Results There were no significant differences in the concentrations of acetic acid and propionic acid between the control and disease groups before and after treatment, as well as no significant changes in the two markers in the disease group after treatment (P > 0.05). The disease group had a significantly increased concentration of butyric acid after treatment (P < 0.05). The concentrations of isobutyric acid and isovaleric acid in the control group were significantly higher than those in the disease group before and after treatment (P < 0.05). Conclusions Intestinal protein metabolites in infants with cholestatic hepatopathy are significantly different from those in healthy infants, whereas there is no significant difference with respect to carbohydrate metabolites.

导出引用

李檬, 刘四香, 王明英, 刘梅, 胡红卫, 丁臻博, 黄永坤. 胆汁淤积性肝病婴儿粪便中细菌相关代谢产物短链脂肪酸水平的分析[J]. 中国当代儿科杂志. 2019, 21(7): 676-679 https://doi.org/10.7499/j.issn.1008-8830.2019.07.011

LI Meng, LIU Si-Xiang, WANG Ming-Ying, LIU Mei, HU Hong-Wei, DING Zhen-Bo, HUANG Yong-Kun. Levels of short-chain fatty acids in enterobacteria-related metabolites in the feces of infants with cholestatic hepatopathy[J]. Chinese Journal of Contemporary Pediatrics. 2019, 21(7): 676-679 https://doi.org/10.7499/j.issn.1008-8830.2019.07.011

参考文献

[1] Fawaz R, Baumann U, Ekong U, et al. Guideline for the evaluation of cholestatic jaundice in infants:joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition[J]. J Pediatr Gastroenterol Nutr, 2017, 64(1):154-168.
[2] 董永绥. 婴儿胆汁淤积性肝病研究进展及展望[J]. 中国实用儿科杂志, 2013, 28(4):241-245.
[3] 胡红卫, 段江, 赵波, 等. 生物标记物粪便胆汁酸的测定在过敏性紫癜患儿诊治中的意义[J]. 中国当代儿科杂志, 2016, 18(6):517-521.
[4] Cummings JH, Pomare EW, Branch WJ, et al. Short chain fatty acids in human large intestine, portal, hepatic and venous blood[J]. Gut, 1987, 28(10):1221-1227.
[5] 胡红卫, 潘媛, 赵波, 等. 过敏性紫癜患儿粪便细菌代谢相关产物短链脂肪酸水平测定及其意义[J]. 中国实用儿科杂志, 2017, 32(7):531-533.
[6] 廖琼, 万朝敏, 朱渝, 等. 婴儿胆汁淤积性肝病在中国的研究现状的可视化分析[J]. 中国当代儿科杂志, 2017, 19(5):529-533.
[7] McCoy KD, Ignacio A, Geuking MB. Microbiota and type 2 immune responses[J]. Curr Opin Immunol, 2018, 54:20-27.
[8] Komaroff AL. The microbiome and risk for atherosclerosis[J]. JAMA, 2018, 319(23):2381-2382.
[9] Zuo T, Kamm MA, Colombel JF, et al. Urbanization and the gut microbiota in health and inflammatory bowel disease[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(7):440-452.
[10] Adolph TE, Grander C, Moschen AR, et al. Liver-microbiome axis in health and disease[J]. Trends Immunol, 2018, 39(9):712-723.
[11] Gonçalves P, Araújo JR, Di Santo JP. A cross-talk between microbiota-derived short-chain fatty acids and the host mucosal immune system regulates intestinal homeostasis and inflammatory bowel disease[J]. Inflamm Bowel Dis, 2018, 24(3):558-572.
[12] Sun M, Wu W, Chen L, et al. Microbiota-derived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis[J]. Nat Commun, 2018, 9(1):3555.
[13] 高晓琳, 万朝敏. 儿童肥胖症与肠道菌群相关性的研究进展[J]. 中国当代儿科杂志, 2017, 19(3):368-371.
[14] 王慧慧, 文飞球, 魏菊荣. 营养不良儿童肠道菌群状况研究进展[J]. 中国当代儿科杂志, 2016, 18(11):1188-1193.
[15] Fushimi T, Tayama K, Fukaya M, et al. Acetic acid feeding enhances glycogen repletion in liver and skeletal muscle of rats[J]. J Nutr, 2001, 131(7):1973-1977.
[16] Tong LC, Wang Y, Wang ZB, et al. Propionate ameliorates dextran sodium sulfate-induced colitis by improving intestinal barrier function and reducing inflammation and oxidative stress[J]. Front Pharmacol, 2016, 7:253.
[17] Kelly CJ, Zheng L, Campbell EL, et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function[J]. Cell Host Microbe, 2015, 17(5):662-671.
[18] Smith EA, Macfarlane GT. Dissimilatory amino acid metabolism in human colonic bacteria[J]. Anaerobe, 1997, 3(5):327-337.
[19] 谢洁玲, 史晓翀, 史姣霞, 等. 人肠道微生物对海带岩藻聚糖硫酸酯及其寡糖的降解利用[J]. 海洋与湖沼, 2017, 48(1):50-56.
[20] Guo C, Li Y, Wang P, et al. Alterations of gut microbiota in cholestatic infants and their correlation with hepatic function[J]. Front Microbiol, 2018, 9:2682.
[21] Koh A, De Vadder F, Kovatcheva-Datchary P, et al. From dietary fiber to host physiology:short-chain fatty acids as key bacterial metabolites[J]. Cell, 2016, 165(6):1332-1345.